To gain novel insights into how therapeutic interventions shape the clonal hierarchy and drive the evolutionary dynamics of FLT3-mutated AML, we conducted a longitudinal analysis of samples collected at the time of diagnosis, during TKI therapy, and at either disease progression (patient 1) or complete remission (CR) (patient 2). Here, FLT3 is linked to acute myeloid leukemia.